ClinicalTrials.gg
RecruitingNCT05660746REMODEL-CDUpdated May 5, 2026

Precise Infliximab Exposure and Pharmacodynamic Control

A Phase 2/3 interventional study of RoadMAB and Infliximab in Crohn Disease, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 11 sites in United States. Open to participants aged 6 Years to 22 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
6 Years to 22 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati — 3 open to participants now, 4 under way, 1 of them phase 3. Crohn Disease · Children's Hospital Medical Center, Cincinnati.

Started
2023
the only one that year
Phase 2/3
2 of 15
1 open now
Registered
12th of 15
by date

Among the 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati, this one is the only one that started in 2023, is one of 2 in phase 2/3, and was the 12th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

3 of the 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 6 Years to 22 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati, or all of them as a file.
02

Study summary

Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment.

The main reason for this research study is to determine if a computer program that calculates an individualized dose based on a patient's blood testing results (precision dosing) can better achieve the best possible response to infliximab compared to standard dosing (conventional dosing).

Read the detailed description

This is an open-label, cluster randomized clinical trial to test whether precision infliximab dosing with a targeted concentration intervention is superior in achieving deep remission (endoscopic healing and clinical remission) compared to patients receiving conventional infliximab dosing.

With recognition that CD patients who achieve the "target" of deep remission with anti-TNF dose optimizations following pharmacodynamic monitoring had a significant reduction in CD-related adverse events, our central hypothesis is precision dosing with infliximab during induction and maintenance will achieve superior rates of deep remission vs. conventional care (control arm)

03

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • Crohn's
04

Who can participate

Ages eligible
6 Years to 22 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written from the patient (≥18 years old) or from parent/legal guardian if patient is \<18 years old
  2. Written informed assent from patient when age appropriate
  3. Diagnosis of Crohn's disease within the last 90 days (luminal-only or luminal with a perianal fistula or abscess treated with antibiotics for at least 7 days)
  4. ≥6 years to ≤22 years of age, anti-TNF naïve and starting infliximab
  5. Clinical activity and luminal inflammation, defined by both (1) and (2)

    • (1) PCDAI≥10 (\<18 years old) or CDAI ≥150 (≥18 years old) in last 60 days before the decision to start infliximab
    • (2) SES-CD>6, or SES-CD>3 for isolated ileal disease (or a report of large intestinal ulcerations)* within the last 60 days or a fecal calprotectin >250 μg/g within last 75 days prior to screening
  6. C-reactive protein >1.0 mg/dL in last 30 days and/or fecal calprotectin >250 μg/g within last 75 days prior to screening
  7. Negative TB (tuberculosis) interferon-gamma release test and a negative urine pregnancy test for female patients (if menstruation has started)

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of ulcerative colitis or inflammatory bowel disease-unspecified
  2. Prior use of anti-TNF therapy (infliximab, adalimumab, certolizumab pegol, or golimumab)
  3. Internal (abdominal/pelvic) penetrating fistula(e) in last 180 days
  4. Intra-abdominal abscess/phlegmon/inflammatory mass in the last 180 days
  5. Active perianal abscess (receiving oral antibiotics for \<7 days)
  6. Intestinal stricture (luminal narrowing with pre-stenotic dilation >3 cm) and surgery planned in the next 90 days
  7. Have tested positive for Clostridium difficile toxin (stool assay) or other intestinal pathogens within 14 days of screening unless a repeat examination is negative and there are no signs of ongoing infection with that pathogen.
  8. Current hospitalization for complications of severe Crohn's disease
  9. Planned use of methotrexate or 6-mercaptopurine (azathioprine) during the induction (first 3 doses of infliximab) phase
  10. Current ileostomy, colostomy, ileoanal pouch, and/or previous extensive small bowel resection (>35 cm) or any CD surgery planned within the next 90 days
  11. History of hepatitis, primary sclerosing cholangitis, thyroiditis, or juvenile idiopathic arthritis
  12. Treatment with another drug in the last four weeks
  13. History of (including lymphoma or leukemia)
  14. Currently receiving treatment for histoplasmosis
  15. History of TB, (HIV), an immunodeficiency syndrome, a central nervous system demyelinating disease, history of heart failure or receiving intravenous antibiotics in last 14 days for any infection
  16. Currently pregnant, breast feeding or plans to become pregnant in the next 1 year
  17. Inability or failure to provide informed assent/consent
  18. Any developmental disabilities that would impede providing assent/consent
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    Conventional dosing

    Induction Phase: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance Phase : 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.

    Drug: Infliximab

  • Experimental
    Precision dosing

    Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.

    Device: RoadMAB · Drug: Infliximab

Interventions

  • DeviceRoadMAB

    The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.

  • Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL. Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.

    Also known as: Avsola, Inflectra, Ixifi, Remicade, Renflexis

06

What researchers measure

Primary outcomes

  1. Rate of Deep Remission

    Pediatric Crohn's disease activity index (PCDAI) \<10 (child) or Crohn's disease activity index\<150 (adult), off prednisone/budesonide for \>8 weeks and Simple Endoscopic Scorer Crohn's Disease (SES-CD) SES-CD≤2

    Time frame: Week 52

Secondary outcomes

  1. Rate of Steroid-free Clinical Remission

    Pediatric Crohn's disease activity index (PCDAI) \<10 (child) or Crohn's disease activity index(CDAI)\<150 (adult) and off prednisone/budesonide for ≥4 weeks

    Time frame: Week 14 and Week 52

  2. Rate of Clinical Response

    Decrease from baseline PCDAI of at least 12.5 points \& total PCDAI\<30 or a PCDAI\<10 (child) or a reduction of CDAI\>70 from baseline or CDAI\<150 (adult)

    Time frame: Week 14 and Week 52

  3. Rate of Primary Clinical Nonresponse

    On prednisone \>16 consecutive weeks from start of infliximab or a PCDAI\>30 or CDAI\>220 for first four infusions

    Time frame: Week 16

  4. Rate of Primary Biologic Nonresponse

    Failure to improve baseline fecal calprotectin by \>100 μg/g (limited to patients with a baseline fecal calprotectin \>250 μg/g) or Failure to improve baseline c-reactive protein ≥0.5 mg/dL (limited to patients with a baseline c-reactive protein \>1.0 mg/dL)

    Time frame: Week 16

  5. Rate of Sustained Steroid-free Remission

    PCDAI\<10 (child) or CDAI\<150 (adult) at dose5 to week52 and off prednisone/budesonide from week 22-52

    Time frame: Week 22 - Week 52

  6. Rate of Steroid-free Remission -biomarker composite

    PCDAI\<10 (child) or CDAI\<150 (adult), off prednisone/budesonide for ≥4 weeks, CRP≤0.5 mg/dL and fecal calprotectin \<250 μg/g

    Time frame: Week 14 and Week 52

  7. Rate of Endoscopic Healing

    Simple endoscopic score-Crohn's disease (SES-CD) ≤2

    Time frame: Week 52

  8. Rate of Complete Endoscopic Healing

    SES-CD=0

    Time frame: Week 52

  9. Rate of Endoscopic Remission

    SES-CD\<4

    Time frame: Week 52

  10. Rate of Mucosal Healing

    SES-CD≤2 and Ileal Global Histologic Activity Score (GHAS)/ Colon Global Histologic Activity Score (CGHAS) ≤2

    Time frame: Week 52

  11. PK Model Bias

    Model predicted vs. actual infliximab concentration. Bias: mean predictive error (MPE)

    Time frame: Week 0 - Week 52

  12. PK Model Precision

    Model predicted vs. actual infliximab concentration. Precision: root mean squared error (RMSE)

    Time frame: Week 0 - Week 52

  13. Rate of IBD related event - Fistula

    Occurrence of fistula and presence of antibody to infliximab \>200 ng/mL

    Time frame: Week 0 - Week 52

  14. Rate of IBD related - Hospitalization

    Occurrence of Crohn's disease related hospitalization

    Time frame: Week 0 - Week 52

  15. Rate of IBD related event - Surgery

    Occurrence of Crohn's disease related surgery

    Time frame: Week 0 - Week 52

  16. Rate of IBD related event - Intestinal stricture

    Occurrence of Crohn's disease related intestinal stricture

    Time frame: Week 0 - Week 52

  17. Rate of IBD related event - Starting corticosteroids

    Occurrence of subjects starting a corticosteroid after week20

    Time frame: Week 0 - Week 52

  18. Rate of IBD related event - Antibodies to infliximab

    Occurrence of antibodies to infliximab defined as \>200 ng/mL

    Time frame: Week 0 - Week 52

  19. Rate of Growth Restoration - Weight change

    In Tanner stage I-III subjects: change in baseline weight (kg) by gender and age group

    Time frame: Week 14 - Week 52

  20. Rate of Growth Restoration- Height velocity

    In Tanner stage I-III subjects: change in height velocity (z-score) by gender

    Time frame: Week 14 - Week 52

  21. PK of infliximab in pediatric patients

    Measured infliximab clearance at baseline and at week52

    Time frame: Week 0 - Week 52

  22. Correlation between infliximab induction exposure and endoscopic remission

    The correlation analysis to be performed for the total area under the curve (infliximab exposure, μg\*h/mL from week0-week14) and patients achieving endoscopic remission. Endoscopic remission is defined as a SES-CD≤2.

    Time frame: Exposure Week 0 - Week 14, Efficacy Week 52

  23. Correlation between infliximab induction exposure and deep remission

    The correlation analysis to be performed for the total area under the curve (infliximab exposure, μg\*h/mL from week0-week14) and patients in deep remission. Deep remission is defined as a PCDAI\<10 (child) or CDAI\<150 (adult), off prednisone/budesonide for \>8 weeks and a SES-CD≤2.

    Time frame: Exposure Week 0 - Week 14, Efficacy Week 52

  24. Patient Reported Outcome-2 (PRO2) Response

    \>50% improvement in total score from baseline

    Time frame: Week 6, Week 14, Week 26, Week 52

  25. Patient Reported Outcome-2 (PRO2) Remission

    Stool frequency ≤3.0 and abdominal pain ≤1.0 (from baseline)

    Time frame: Week 6, Week 14, Week 26, Week 52

  26. Quality of Life & Disability -IMPACT-III score

    Total IMPACT-III (child) score

    Time frame: Week 52

  27. Quality of Life & Disability - Inflammatory Bowel Disease Disk score

    Total Inflammatory Bowel Disease Disk (without sexual function assessment) score

    Time frame: Week 52

  28. Quality of Life & Disability - Short Inflammatory Bowel Disease score

    Total Short IBD Questionnaire (adult) score

    Time frame: Week 52

  29. Process Evaluation -Usability of Decision Support Tool

    Total System Usability Scale score

    Time frame: Week 0 - Week 52

  30. Rate of Adverse events

    Number of Adverse Events

    Time frame: Week 0 - Week 52

  31. Rate of Serious Adverse events

    Number of Serious Adverse Events

    Time frame: Week 0 - Week 52

07

Study locations

11 of 11 sites recruiting
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
    Recruiting
    • Mallory Chavannes · Contact
    • Mallory Chavannes, MD · Principal investigator
  • Lucile Packard Children's Hospital Stanford
    Palo Alto, California 94304, United States
    Recruiting
    • Alka Goyal · Contact
    • Alka Goyal, MD · Principal investigator
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
    Recruiting
    • Laura Bauman · Contact
    • Laura Bauman, MD · Principal investigator
  • Nemours Children's Health System-Wilmington
    Wilmington, Delaware 19803, United States
    Recruiting
    • Zarela Molle-Rios · Contact
    • Zarela Molle-Rios, MD · Principal investigator
  • Nemours Children's Health System-Jacksonville
    Jacksonville, Florida 32207, United States
    Recruiting
    • Jill Dorsey · Contact
    • Jill Dorsey, MD · Principal investigator
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Steven Steiner · Contact
    • Steven Steiner, MD · Principal investigator
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
    Recruiting
  • Cleveland Clinic Children's Hospital
    Cleveland, Ohio 44106, United States
    Recruiting
    • Jacob Kurowski · Contact
    • Jacob Kurowski, MD · Principal investigator
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
    Recruiting
    • Brendan Boyle · Contact
    • Brendan Boyle · Principal investigator
  • Children's Specialty Group
    Norfolk, Virginia 23507, United States
    Recruiting
  • Medical College of Wisconsin, Children's of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Joshua Noe · Contact
    • Joshua Noe, MD · Principal investigator
08

References and documents

Publications

  • Minar PP, Colman RJ, Zhang N, Mizuno T, Vinks AA. Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA. BMJ Open. 2024 Mar 25;14(3):e077193. doi: 10.1136/bmjopen-2023-077193. PubMed 38531570 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Mar 2027, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Dec 21, 2022
StartActual
Jul 1, 2023
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05660746
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Jul 1, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
May 5, 2026

Study contacts

Phillip Minar, MD, MS
Contact
phillip.minar@cchmc.org
513-636-4415
Phillip Minar, MD,MS
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion